{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:08:44Z","timestamp":1786975724321,"version":"build-2736575974"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1001\/jamaneurol.2019.0447","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T11:04:23Z","timestamp":1554116663000},"page":"783","source":"Crossref","is-referenced-by-count":39,"title":["Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy"],"prefix":"10.1001","volume":"76","author":[{"given":"Hyunmi","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Neurology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Faught","sequence":"additional","affiliation":[{"name":"Department of Neurology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Thurman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Fishman","sequence":"additional","affiliation":[{"name":"UCB Pharma, Smyrna, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Kalilani","sequence":"additional","affiliation":[{"name":"UCB Pharma, Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"noi190013r1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1474-4422(12)70103-5","article-title":"Teratogenic effects of antiepileptic drugs.","volume":"11","author":"Tomson","year":"2012","journal-title":"Lancet Neurol"},{"issue":"11","key":"noi190013r2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1528-1157.2000.tb00119.x","article-title":"Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE).","volume":"41","author":"Arpino","year":"2000","journal-title":"Epilepsia"},{"issue":"3","key":"noi190013r3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/WNL.0000000000002119","article-title":"Developmental effects of antiepileptic drugs and the need for improved regulations.","volume":"86","author":"Meador","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"noi190013r4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"noi190013r5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000318293.28278.33","article-title":"Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.","volume":"71","author":"Hunt","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"noi190013r6","doi-asserted-by":"crossref","first-page":"405.e1","DOI":"10.1016\/j.ajog.2012.07.008","article-title":"Use of topiramate in pregnancy and risk of oral clefts.","volume":"207","author":"Margulis","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"noi190013r7","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1212\/WNL.0000000000004857","article-title":"Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study.","volume":"90","author":"Hernandez-Diaz","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"noi190013r8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/AOG.0000000000000018","article-title":"Association between topiramate and zonisamide use during pregnancy and low birth weight.","volume":"123","author":"Hern\u00e1ndez-D\u00edaz","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"16","key":"noi190013r9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"key":"noi190013r10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2015.04.016","article-title":"Cognitive outcomes of prenatal antiepileptic drug exposure.","volume":"114","author":"Inoyama","year":"2015","journal-title":"Epilepsy Res"},{"issue":"4","key":"noi190013r11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1212\/WNL.0000000000001182","article-title":"IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study.","volume":"84","author":"Baker","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"noi190013r12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.yebeh.2011.04.009","article-title":"Cognitive and neurodevelopmental effects of antiepileptic drugs.","volume":"22","author":"Bromley","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"3","key":"noi190013r13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"issue":"16","key":"noi190013r14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1212\/WNL.0b013e318250d824","article-title":"Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years.","volume":"78","author":"Meador","year":"2012","journal-title":"Neurology"},{"issue":"pt 2","key":"noi190013r15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/brain\/awq352","article-title":"Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age.","volume":"134","author":"Meador","year":"2011","journal-title":"Brain"},{"issue":"2","key":"noi190013r16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.yebeh.2011.06.014","article-title":"Fetal antiepileptic drug exposure: motor, adaptive, and emotional\/behavioral functioning at age 3 years.","volume":"22","author":"Cohen","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"16","key":"noi190013r17","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"noi190013r18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1212\/WNL.0b013e3181a6b312","article-title":"Practice parameter update: management issues for women with epilepsy\u2014focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.","volume":"73","author":"Harden","year":"2009","journal-title":"Neurology"},{"issue":"10","key":"noi190013r19","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1212\/WNL.0000000000001772","article-title":"Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study.","volume":"85","author":"Tomson","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"noi190013r22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.yebeh.2009.04.026","article-title":"Antiepileptic drug use in women of childbearing age.","volume":"15","author":"Meador","year":"2009","journal-title":"Epilepsy Behav"},{"issue":"9","key":"noi190013r23","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1212\/WNL.0000000000001304","article-title":"Antiepileptic drug use by pregnant women enrolled in Florida Medicaid.","volume":"84","author":"Wen","year":"2015","journal-title":"Neurology"},{"key":"noi190013r24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yebeh.2018.04.009","article-title":"Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy.","volume":"84","author":"Meador","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"7","key":"noi190013r25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet Neurol"},{"issue":"2","key":"noi190013r26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.2005.074203","article-title":"Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.","volume":"77","author":"Morrow","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"noi190013r27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.yebeh.2016.11.018","article-title":"Epilepsy treatment in adults and adolescents: expert opinion, 2016.","volume":"69","author":"Shih","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"6","key":"noi190013r28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/adc.2008.144386","article-title":"Changing trends in antiepileptic drug prescribing in girls of child-bearing potential.","volume":"94","author":"Ackers","year":"2009","journal-title":"Arch Dis Child"},{"issue":"1","key":"noi190013r29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2009.07.005","article-title":"Antiepileptic drugs in epilepsy and other disorders\u2013a population-based study of prescriptions.","volume":"87","author":"Johannessen Landmark","year":"2009","journal-title":"Epilepsy Res"},{"issue":"7","key":"noi190013r30","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/aogs.13109","article-title":"Women treated for epilepsy during pregnancy: outcomes from a nationwide population-based cohort study.","volume":"96","author":"Artama","year":"2017","journal-title":"Acta Obstet Gynecol Scand"},{"key":"noi190013r31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1528-1167.2011.03121.x","article-title":"Standards for epidemiologic studies and surveillance of epilepsy.","volume":"52","author":"Thurman","year":"2011","journal-title":"Epilepsia"},{"issue":"2","key":"noi190013r32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.0013-9580.2005.30604.x","article-title":"Estimating prevalence, incidence, and disease-related mortality for patients with epilepsy in managed care organizations.","volume":"46","author":"Holden","year":"2005","journal-title":"Epilepsia"},{"issue":"6","key":"noi190013r33","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/epi.13001","article-title":"Descriptive epidemiology of epilepsy in the US population: A different approach.","volume":"56","author":"Helmers","year":"2015","journal-title":"Epilepsia"},{"issue":"2","key":"noi190013r34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1212\/WNL.0000000000005755","article-title":"Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"noi190013r35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00228-017-2252-0","article-title":"Erratum to: Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders\u2014a pharmacoepidemiological study and clinical implications.","volume":"73","author":"Baftiu","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"noi190013r36","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00228-016-2092-3","article-title":"Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications.","volume":"72","author":"Baftiu","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"noi190013r37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2011.03.011","article-title":"Antiepileptic drugs in the treatment of psychiatric disorders.","volume":"21","author":"Kaufman","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"6","key":"noi190013r38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/bdra.23147","article-title":"Valproate prescriptions for nonepilepsy disorders in reproductive-age women.","volume":"97","author":"Adedinsewo","year":"2013","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"noi190013r39","doi-asserted-by":"crossref","first-page":"j4426","DOI":"10.1136\/bmj.j4426","article-title":"Women still not being told about pregnancy risks of valproate.","volume":"358","author":"Wise","year":"2017","journal-title":"BMJ"},{"issue":"5","key":"noi190013r40","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5603\/GP.a2017.0053","article-title":"Managing epilepsy in women of childbearing age\u2014Polish Society of Epileptology and Polish Gynecological Society Guidelines.","volume":"88","author":"Jedrzejczak","year":"2017","journal-title":"Ginekol Pol"},{"issue":"3","key":"noi190013r41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984.","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"issue":"6","key":"noi190013r42","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4065\/71.6.576","article-title":"Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota.","volume":"71","author":"Hauser","year":"1996","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"noi190013r43","doi-asserted-by":"crossref","first-page":"e1031","DOI":"10.1212\/WNL.0000000000006173","article-title":"Unintended pregnancy, prenatal care, newborn outcomes, and breastfeeding in women with epilepsy.","volume":"91","author":"Johnson","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"noi190013r44","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/epi.13320","article-title":"Contraceptive practices of women with epilepsy: Findings of the epilepsy birth control registry.","volume":"57","author":"Herzog","year":"2016","journal-title":"Epilepsia"},{"issue":"RR-14","key":"noi190013r45","first-page":"1","article-title":"Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects.","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"noi190013r46","first-page":"5","article-title":"Use of supplements containing folic acid among women of childbearing age\u2014United States, 2007.","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"noi190013r47","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.yebeh.2017.05.007","article-title":"Folic acid use by women with epilepsy: Findings of the Epilepsy Birth Control Registry.","volume":"72","author":"Herzog","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"18","key":"noi190013r48","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1212\/WNL.0000000000006425","article-title":"Quality improvement in neurology: Epilepsy Quality Measurement Set 2017 update.","volume":"91","author":"Patel","year":"2018","journal-title":"Neurology"},{"key":"noi190013r20","unstructured":"US Food and Drug Administration. FDA drug safety communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm350684.htm. Updated February 26, 2016. Accessed October 15, 2018."},{"key":"noi190013r21","unstructured":"Gov.UK. Valproate use by women and girls. 2018; https:\/\/www.gov.uk\/guidance\/valproate-use-by-women-and-girls#toolkit. Updated December 18, 2018. Accessed October 15, 2018."}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaneurology\/article-pdf\/76\/7\/783\/17684620\/jamaneurology_kim_2019_oi_190013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T11:01:59Z","timestamp":1562583719000},"score":1,"resource":{"primary":{"URL":"http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2019.0447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.0447","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}